Rituximab and CHOP-like chemotherapy in good-prognosis diffuse large-B-cell lymphoma: Commentary

Nature Clinical Practice Oncology

Volumn 3, Issue 11, 2006, Pages 594-595

  Coiffier, Bertrand ^a  

^a HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; HISTOLOGY; HUMAN; LARGE CELL LYMPHOMA; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK REDUCTION; SHORT SURVEY; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

EID: 33750560444     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0638     Document Type: Short Survey

References (5)

1. Coiffier B et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242
2. Feugier P et al. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23: 4117-4126
3. Pfreundschuh M et al. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104: 626-633
4. Reyes F et al. (2005) ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352: 1197-1205
5. Habermann TM et al. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24: 3121-3127